AELIS FARMA
Created in 2013
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
105 4,367Activities
Technologies
Entity types
Location
1 Rue Lafaurie de Monbadon, 33000 Bordeaux, France
Bordeaux
France
Employees
Scale: 11-50
Estimated: 31
SIREN
797707627Engaged corporates
7
2 5Added in Motherbase
3 years ago
biotech Value proposition
A clinical stage biotech company opening a new frontier in pharmacology
Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases.
Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments.
These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.
Two initial drug candidates are already in clinical trials in indications with high unmet medical needs:
• AEF0117, to treat disorders due to excessive cannabis use, has already provided evidence of efficacy in a phase 2a clinical study and has entered a phase 2b clinical trial in Q2 2022.
• AEF0217, to treat various cognitive deficits, including those associated with Down syndrome (Trisomy 21), is currently being evaluated in phase 1 clinical trials, with no major adverse effects observed in the three patient cohorts treated to date. Phase 1/2 clinical studies with AEF0217 in Down syndrome subjects are expected to start in Q4 2022. These studies could provide initial efficacy results in H1 2023.
Given the involvement of the CB1 receptor in numerous pathologies, Aelis Farma is also developing using its proprietary platform, several new CB1-SSi with differentiated pharmacological properties to target other brain pathologies.
Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.
Biotechnology, Central Nervous System, Innovative signaling specific drugs, CB1 receptor, Allosteric modulator, Cannabis addiction, Cognitive Disorders, Down syndrome, Fragil X syndrom, obesity, metabolic disorders, and cannabis use disordersOriginal language
A clinical stage biotech company opening a new frontier in pharmacology
Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases.
Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments.
These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.
Two initial drug candidates are already in clinical trials in indications with high unmet medical needs:
• AEF0117, to treat disorders due to excessive cannabis use, has already provided evidence of efficacy in a phase 2a clinical study and has entered a phase 2b clinical trial in Q2 2022.
• AEF0217, to treat various cognitive deficits, including those associated with Down syndrome (Trisomy 21), is currently being evaluated in phase 1 clinical trials, with no major adverse effects observed in the three patient cohorts treated to date. Phase 1/2 clinical studies with AEF0217 in Down syndrome subjects are expected to start in Q4 2022. These studies could provide initial efficacy results in H1 2023.
Given the involvement of the CB1 receptor in numerous pathologies, Aelis Farma is also developing using its proprietary platform, several new CB1-SSi with differentiated pharmacological properties to target other brain pathologies.
Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.
Home - AelisFarma
Aelis Farma is a biotechnology company specialized in the treatment of brain disorders
https://www.aelisfarma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Le Figaro Media, Newspaper Publishing | Le Figaro Media, Newspaper Publishing | Other 25 Mar 2025 | | |
 Le Journal des Entreprises Media, Newspaper Publishing | Le Journal des Entreprises Media, Newspaper Publishing | Other 17 Jan 2024 | | |
 Région Nouvelle-Aquitaine National and local authorities, Government Administration | Région Nouvelle-Aquitaine National and local authorities, Government Administration | Other 3 Dec 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 5 Dec 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 16 May 2023 | | |
 EY Consulting, audit, IT Services and IT Consulting | EY Consulting, audit, IT Services and IT Consulting | Other 4 Oct 2022 | | |
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Other 14 Mar 2024 | | |